Stay updated on IONIS-FB-LRx in Primary IgA Nephropathy Clinical Trial
Sign up to get notified when there's something new on the IONIS-FB-LRx in Primary IgA Nephropathy Clinical Trial page.

Latest updates to the IONIS-FB-LRx in Primary IgA Nephropathy Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe Publications section was updated to indicate PubMed auto-fills publications and may not be about the study, and to display Revision: v3.3.2. The previous PubMed note (Revision: v3.2.0) was removed.SummaryDifference0.1%

- Check28 days agoChange DetectedRemoved the generic government funding/status notice from the page. Study-specific details such as the title, NCT number, eligibility criteria, and outcome measures remain unchanged.SummaryDifference0.4%

- Check42 days agoChange DetectedThe new screenshot shows only minor layout changes and a banner variation with no changes to core trial information such as eligibility criteria, endpoints, enrollment, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check71 days agoChange DetectedKey updates: version bump to v3.2.0 and an important government-operating-status notice; the previous v3.1.0 reference was removed. Overall, user-facing status and versioning information were updated. If no other content changed, this is a targeted update to status and versioning.SummaryDifference5%

- Check78 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.1%

- Check93 days agoChange DetectedVersion bumped from v3.0.1 to v3.0.2, indicating a minor update; removal of 'Back to Top' is a small UI change and does not affect core content.SummaryDifference0.3%

Stay in the know with updates to IONIS-FB-LRx in Primary IgA Nephropathy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IONIS-FB-LRx in Primary IgA Nephropathy Clinical Trial page.